SCHEMBL27337702

SCHEMBL27337702

C[Si]1(C)CC[Si](C)(C)c2cc(-c3cc(-c4ccc(C(=O)O)cc4)ccc3OCCCO)ccc21

nearest known ligand 0.66

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
RARG P13631 19/20 0.66
RARB P10826 18/20 0.66
RARA P10276 16/20 0.66
PTPN11 Q06124 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27337698 0.96 RARG (0.60) RARGRARBRARA
SCHEMBL27337626 0.91 RARG (0.55) RARGRARBRARA
SCHEMBL27337627 0.87 RARG (0.49) RARGRARBRARA
SCHEMBL344900 0.80 RARG (1.00) RARGRARBRARA
SCHEMBL27337666 0.78 RARB (0.41) RARGRARBRARA
SCHEMBL27337979 0.77 RARG (0.62) RARGRARBRARAPTPN11
SCHEMBL345684 0.77 RARG (1.00) RARGRARBRARA
SCHEMBL382001 0.76 RARG (1.00) RARGRARBRARAPTPN11
SCHEMBL27337657 0.76 RARB (0.40) RARGRARBRARA
SCHEMBL27338665 0.76 RARB (0.40) RARGRARBRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217992-A1 RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) 2024-07-04 US disclosed
US-20240217992-A1 RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) 2024-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217992-A1 RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE RARA, RARG, RXRG RARG 2/4885RARB 4/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.